Yip Pui Lam, You Rui, Chen Ming-Yuan, Chua Melvin L K
Department of Radiation Oncology, National University Cancer Institute, National University Hospital, Singapore 119074, Singapore.
Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
Cancers (Basel). 2024 Jan 16;16(2):383. doi: 10.3390/cancers16020383.
Radiotherapy is the primary treatment modality for non-metastatic nasopharyngeal carcinoma (NPC) across all TN-stages. Locoregional control rates have been impressive even from the 2D radiotherapy (RT) era, except when the ability to deliver optimal dose coverage to the tumor is compromised. However, short- and long-term complications following head and neck RT are potentially debilitating, and thus, there has been much research investigating technological advances in RT delivery over the past decades, with the primary goal of limiting normal tissue damage. On this note, with a plateau in gains of therapeutic ratio by modern RT techniques, future advances have to be focused on individualization of RT, both in terms of dose prescription and the delineation of target volumes. In this review, we analyzed the guidelines and evidence related to contouring methods, and dose prescription for early and locoregionally advanced (LA-) NPC. Next, with the preference for induction chemotherapy (IC) in patients with LA-NPC, we assessed the evidence concerning radiotherapy adaptations guided by IC response, as well as functional imaging and contour changes during treatment. Finally, we discussed on RT individualization that is guided by EBV DNA assessment, and its importance in the era of combinatorial immune checkpoint blockade therapy with RT.
放射治疗是所有TN分期的非转移性鼻咽癌(NPC)的主要治疗方式。即使在二维放射治疗(RT)时代,局部区域控制率也令人印象深刻,除非向肿瘤提供最佳剂量覆盖的能力受到损害。然而,头颈部放疗后的短期和长期并发症可能使人衰弱,因此,在过去几十年里,人们进行了大量研究来探索放疗技术的进步,主要目标是限制正常组织损伤。就此而言,由于现代放疗技术在治疗比方面的提升已趋于平稳,未来的进展必须集中在放疗的个体化上,包括剂量处方和靶区勾画。在这篇综述中,我们分析了与早期和局部区域晚期(LA-)NPC的轮廓勾画方法和剂量处方相关的指南及证据。接下来,鉴于LA-NPC患者倾向于接受诱导化疗(IC),我们评估了有关根据IC反应调整放疗的证据,以及治疗期间的功能成像和轮廓变化。最后,我们讨论了由EBV DNA评估指导的放疗个体化及其在放疗联合免疫检查点阻断治疗时代的重要性。